S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
Arterial Stiffness Predicts Incident Atrial Fibrillation in the Framingham Heart Study: A Mechanistic Contribution in People With High Blood Pressure or History of Hypertension
TL;DR: It is confirmed in a slightly different type of population that left ventricular hypertrophy is a strong predictor of AF, and suggests that AF is in most cases a typical complication of hypertension, and even more so than stroke or heart failure.
Journal ArticleDOI
Sex differences in essential hypertension.
TL;DR: A group of 41‐year‐old hypertensive men and women who had never received treatment for their condition were compared with hypertensive women of the same age, finding that women with BMI above 25 kg m−2 had significantly lower arterial plasma adrenaline and noradrenaline than those with BMI below 25 kgm−2.
Journal ArticleDOI
Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy
Frej Fyhrquist,A. Eriksson,Outi Saijonmaa,Børge G. Nordestgaard,Kimmo Kontula,Ulf de Faire,Hans Ibsen,Sverre E. Kjeldsen,Ingrid Os,Björn Dahlöf +9 more
TL;DR: Shorter LTL in genotypes DD or ID suggests a negative effect of the D allele on telomere length, which appears to strengthen the association of telomeres length with increased cardiovascular risk in elderly hypertensive subjects with LVH.
Journal ArticleDOI
The Global Burden of Disease Study 2015 and Blood Pressure.
TL;DR: The Global Burden of Disease report concludes that achievement of optimalBlood pressure in the population would yield large potential gains in global health and that study of blood pressure in people younger than 60 years of age is an important area for future investigation.
Journal ArticleDOI
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
Derek Weycker,John Edelsberg,G Vincze,Sverre E. Kjeldsen,K Jamerson,Zeba M. Khan,Gerry Oster +6 more
TL;DR: This study corroborates the finding from VALUE that diabetes risk is lower for patients who receive valsartan versus amlodipine, and extends this finding to a ‘real-world’ setting.